A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Trial Profile

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs MGTA 456 (Primary)
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Sponsors Magenta Therapeutics
  • Most Recent Events

    • 25 Jan 2018 New trial record
    • 23 Jan 2018 Status has been not yet recruiting to Recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top